On Friday, Cantor Fitzgerald reaffirmed its Overweight rating on Cipher Mining shares (NASDAQ:CIFR), with a set price target of $11.00. The firm's analyst, Brett Knoblauch, provided insight into ...

Cantor Fitzgerald initiated coverage of Acrivon Therapeutics (ACRV) with an Overweight rating without a price target The company has two clinical assets and a next-generation precision medicine ...

In a report released yesterday, C J Muse from Cantor Fitzgerald maintained a Hold rating on KLA (KLAC – Research Report), with a price target of $875.00. The company’s shares closed yesterday ...

Fintel reports that on January 29, 2025, Cantor Fitzgerald upgraded their outlook for Beam Therapeutics (NasdaqGS:BEAM) from Neutral to Overweight. As of January 29, 2025, the average one-year ...

The billionaire tapped to head up President Donald Trump’s Commerce Department has vowed to sell his business holdings within 90 days as he pursues senatorial confirmation. Howard Lutnick ...

Andres Sheppard at Cantor Fitzgerald said in an interview that he saw a couple of positives in the report that may have prompted investors to look past the miss. "I personally think the biggest ...

On Wednesday, Cantor Fitzgerald initiated coverage on Galaxy Digital Holdings Ltd (TSX:GLXY:CN) (OTC: BRPHF), assigning an Overweight rating to the company's stock with a price target of Cdn$44.00.

Cantor Fitzgerald has a convertible bond with Tether, incoming Commerce Secretary Howard Lutnick said at his confirmation hearing, confirming previous reporting by The Wall Street Journal that ...

This month, Flagstar offloaded $142 million of that portfolio, finding a buyer in Howard Lutnick’s Cantor Fitzgerald, PincusCo reported. A spokesperson for Cantor Fitzgerald did not return a ...

Cantor Fitzgerald currently has a “Overweight” rating and a $50.00 price target on the stock. The consensus estimate for Septerna’s current full-year earnings is ($7.11) per share. Get ...

Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Fate Therapeutics in a report issued on Tuesday ...